Fig. 1
From: A novel mechanism for A-to-I RNA-edited CYP1A1 in promoting cancer progression in NSCLC
CYP1A1 overediting is strongly associated with NSCLC pathogenesis. A CYP1A1 editing of serum samples from patients with NSCLC and non-NSCLC cohorts. B The CYP1A1 editing level in a cohort of 103 NSCLC patients stratified by stage. C Dot plots showing CYP1A1 editing in serum samples, primary NSCLC, and normal adjacent tissues (NATs) from 103 patients. The p values shown were calculated by Mann–Whitney U test. The matched NSCLC specimens were subdivided into four categories according to the presence or absence of smoking history or tumor recurrence. Association between smoking history (D) or recurrence incidence (E) with CYP1A1 overediting (χ2 test). (F) Kaplan–Meier plots for the disease-free survival rate of patients with NSCLC in the groups with (+) and without (−) CYP1A1 overediting. The p value shown was calculated by log rank test